Vaccination of 'mid-adults,' including those at higher risk, results in higher number needed to vaccinate than that seen for younger people ...

AXS-12 reduced the frequency of cataplexy attacks per week compared with placebo (P =.017). Topline results were announced from a phase 3 trial evaluating AXS-12 (reboxetine) in patients with ...

There was an increase in quarterly prescription rates from 4.2% in July to September 2021 to 23.5% in July to September 2023. (HealthDay News) — From 2021 to 2023, there was an increase in ...

According to Soleno Therapeutics, the FDA required more time to review responses to recent information requests.

STS101 is an investigational DHE nasal powder product administered through a proprietary nasal delivery device.

Seasonal maternal RSV vaccination may be cost-effective, as well as nirsevimab, particularly for those with higher risks ...

(HealthDay News) — Exposure to certain antiseizure medications (ASMs) in utero is associated with an increased likelihood of neurodevelopmental diagnoses, according to a study published online Nov. 15 ...

The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...

According to the Company, detailed results will be presented at a medical meeting in 2025. A phase 3 trial evaluating tiragolumab in combination with Tecentriq ® (atezolizumab) in adults with PD-L1 ...

Simufilam is an investigational oral small molecule that targets the filamin A protein. In the ReThink-ALZ study (ClinicalTrials.gov Identifier: NCT04994483 ), patients with confirmed mild or moderate ...

Participants were randomly assigned to receive subcutaneous sotatercept or placebo every 21 days with background PAH therapy. The primary endpoint was the time to first confirmed morbidity or ...

No long-term cognitive effects of mHT were seen in the KEEPS Continuation study, about 10 years after completion of randomized treatment ...